"AbbVie’s Skyrizi generated $5.01B in Q4, up 32.5% year over year, making it AbbVie’s largest product, while Rinvoq added $2.37B, up 29.5%."
"Pfizer’s revenue came in at $17.56B, down 1.2% year over year, but the non-COVID portfolio grew 9% operationally, with Eliquis contributing $2.02B."
"AbbVie generated $17.82B in free cash flow in FY 2025 against $11.66B in dividend payments, resulting in a coverage ratio of 1.53x."
"Pfizer’s free cash flow in FY 2025 was $9.08B, while dividend payments totaled $9.77B, leading to a concerning coverage ratio of 0.93x."
AbbVie reported strong fourth-quarter earnings, driven by Skyrizi and Rinvoq, which replaced Humira. AbbVie's immunology segment revenue grew significantly. In contrast, Pfizer's revenue declined slightly, with its non-COVID portfolio performing well but COVID-related products seeing substantial drops. Pfizer's dividend yield appears attractive, but its free cash flow does not cover dividend payments, raising sustainability concerns. AbbVie, with a strong free cash flow and consistent dividend growth, presents a more stable income stream for investors compared to Pfizer's uncertain dividend outlook.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]